Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by D Slade
Escalating-Dose HLA-mismatched DLI Is Safe for the Treatment of Leukaemia Relapse Following Alemtuzumab-Based Myeloablative Allo-SCT
Bone Marrow Transplantation
Transplantation
Hematology
Related publications
Clinical and Biological Predictors of Outcome Following Relapse of CML Post-Allo-SCT
Bone Marrow Transplantation
Transplantation
Hematology
Occult Autologous Haematopoietic Regeneration Without Disease Relapse Following Myeloablative Allogeneic Haematopoietic SCT for Lymphomas
Bone Marrow Transplantation
Transplantation
Hematology
Escalating Doses of Donor Lymphocytes for Incipient Graft Rejection Following SCT for Thalassemia
Bone Marrow Transplantation
Transplantation
Hematology
Outpatient Myeloablative Allo-Sct: A Comprehensive Approach Yields Decreased Hospital Utilization and Low TRM
Bone Marrow Transplantation
Transplantation
Hematology
Enteral Nutrition: A First Option for Nutritional Support of Children Following Allo-Sct?
Bone Marrow Transplantation
Transplantation
Hematology
The Impact of Graft Composition on Clinical Outcomes in Unmanipulated HLA-mismatched/haploidentical Hematopoietic SCT
Bone Marrow Transplantation
Transplantation
Hematology
HLA-identical Haematopoietic Stem Cell Transplantation for Acute Leukaemia in Children: Less Relapse With Higher Biologically Effective Dose of TBI
Bone Marrow Transplantation
Transplantation
Hematology
Full-Dose 90Y Ibritumomab Tiuxetan Therapy Is Safe in Patients With Prior Myeloablative Chemotherapy
Clinical Cancer Research
Cancer Research
Oncology
Alemtuzumab Markedly Reduces Chronic GVHD Without Affecting Overall Survival in Reduced-Intensity Conditioning Sibling Allo-SCT for Adults With AML
Bone Marrow Transplantation
Transplantation
Hematology
